F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

FAPON is a biotechnology company that provides IVD reagent raw material manufacturing and a one-stop solution. The company provides excellent-performance IVD reagent core raw materials, reagent solutions, and open solutions to global in vitro diagnostic companies. In the field of high-performance in vitro diagnostic reagents, various bioengineering technologies are used, as well as precise screening and the provision of active raw materials.

Dongguan Pengzhi Biotechnology Co., Ltd., established on 2016-08-22, Business scope includes biological products,R&D of medical devices,Production,Sales and technology transfer,Technical Services;Sales:Chemical Products(Free of Hazardous Chemicals);Import and export,Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Roche Diagnostics GmbH, part of Roche Holding AG, is a company headquartered in Mannheim, Germany, involved in laboratory analytical instruments. Andreas Schmitz and Claus Haberda are the current co-CEOs of the firm. On January 01, 1999 Roche Holding AG acquired Roche Diagnostics GmbH.

Roche Diagnostics Operations, Inc. provides healthcare services. It offers commercial physical and biological research and development. The company is headquartered in Indianapolis, IN.

Singulex, Inc., a biotechnology company, develops and commercializes direct molecular detection technology solutions. Its solutions enable life science researchers and clinicians to understand and manage disease. The company develops biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers. It is conducting pilot studies to validate Erenna BioAssay System, a digital molecule detection platform, which detects and quantifies molecule biomarkers in clinical samples. The company also offers various custom assay services, such as pilot study services, assay prototyping, assay characterization, and assay validation. The company was formerly known as BioProfile Corporation and changed its name to Singulex, Inc in September 2003. Singulex is based in Hayward, California

Guangdong Feipeng Biological Co., Ltd., established on 2013-12-25, Business scope includes biological products(Does not contain drugs)research and development,production and sales;medical instruments,In vitro diagnostic reagents(the first sort,second category,third category)production and sales;Import and export of goods or technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Sensor-Kinesis Corp. (“SKC”) is a development stage hi-tech company that is developing proprietary, flexible micro biosensor integrated computer chips suitable for printing on many surfaces. These chips which detect certain biomolecules can be linked to smart devices and shared via cloud technology. SKC’s chips are being developed to detect and measure biological signals and data from humans and then use smart devices to transmit the information for analysis and storage. The application for this technology is both universal and versatile across entire industries including healthcare, infectious disease, food safety, pharmaceuticals, medical devices, agriculture, laboratories, biodefense, and transportation. The company's goal is to provide a proprietary innovation that will allow physicians, health and safety organizations, and individuals the ability to detect diseases and other detractors to our health and well-being at a lower limit-of-detection in a single portable low-cost device.

Fujirebio, Inc. engages in the manufacture, sale, import and export of clinical diagnostic reagents and assay instruments. It also provides diagnostic, clinical laboratory testing and related services. The company was founded on December 18, 1950 and is headquartered in Tokyo, Japan.

Roche Diagnostics Corp. develops and manufactures diagnostic products. It offers anticoagulation management, blood gas and electrolytes, cholesterol and urinalysis products. The firm provides a broad portfolio of tools that help healthcare providers in the prevention, diagnosis and management of diseases like HPV, HIV, heart failure and diabetes, as well as other medical conditions, such as fertility and blood coagulation. Its products and services uses by researchers, physicians, patients, hospitals and laboratories worldwide. The company was founded in 1964 by Willard Eason and is headquartered in Indianapolis, IN.

Hunan Yonghe Sunshine Biotechnology Co., Ltd., established on 2006-03-17, Business scope includes biotechnology development services;Medical Device Technology Development;Medical device technology transfer service;Medical equipment rental service;Medical device technical consultation,communication service;Self-operated and agent import and export of various commodities and technologies,Except for the goods and technologies that the state restricts the company to operate or prohibits the import and export of;Class I medical device,Class II medical device,Class III medical device sales;Biological product,Class II medical device,Class III Medical Devices,Class II:6840In vitro diagnostic reagents,Class II:6840Production of clinical laboratory analysis instruments.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Guangdong Weishi Biotechnology Co., Ltd., established on 2019-12-27, Business scope includes medical devices(the first sort,second category,third category),In vitro diagnostic reagents(the first sort,second category,third category)research and development,Production,Sales;Biotechnology R&D;Research and development of biological products(Does not contain drugs);R&D of instrumentation,Production,Sales;Computer software development,Sales;biomedicine,Medical technology research and development,technology transfer;Import and export of goods or technology(Except for the import and export of goods or technologies prohibited by the state or approved by the government).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Stealth BioTherapeutics, Inc., part of Stealth BioTherapeutics Corp., is a company headquartered in Newton, MA, that develops therapies to treat the mitochondrial dysfunctions and age-related diseases. The firm was founded in 2007. Irene P. McCarthy is the current CEO, occupying that position since 2009.\nThe company says this about itself: The Company is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases and are involved in many common age-related diseases, typically involving organ systems with high energy demands such as the eye, the neuromuscular system, the heart and the brain. The Company believes that its lead product candidate, elamipretide, has the potential to treat ophthalmic diseases, such as dry AMD, rare neuromuscular disorders, such as primary mitochondrial myopathy, and rare cardiomyopathies, such as Barth syndrome. The Company has a deep pipeline of novel mitochondria-targeted compounds under evaluation as therapeutic product candidates.

Shenzhen New Industries Biomedical Engineering Co., Ltd. principally engages in the research, development, production, and sale of automatic chemiluminescence immunoassay instruments and supporting reagents. The company was founded on December 15, 1995 and is headquartered in Shenzhen, China.

Otago Innovation Ltd. engages in research and developments. The firm is a University of Otago company responsible for developing and commercializing the University's intellectual property. The company was founded in 2002 and is headquartered in Dunedin, New Zealand.